drug_type
RELEVANT_DRUG
intervention_type
Bispecific T-cell engager (antibody-based biologic)
drug_description
DLL3xCD3 bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells to redirect and activate cytotoxic T-cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific T-cell–engaging antibody that binds DLL3 on tumor cells and CD3 on T cells, forming an immune synapse to activate and redirect cytotoxic T cells to kill DLL3-expressing cancer cells.
drug_name
BI 764532 (obrixtamig)
nct_id_drug_ref
NCT06077500